Improved Outcomes with Enzalutamide in Biochemically Recurrent Prostate Cancer
- PMID: 37851874
- DOI: 10.1056/NEJMoa2303974
Improved Outcomes with Enzalutamide in Biochemically Recurrent Prostate Cancer
Abstract
Background: Patients with prostate cancer who have high-risk biochemical recurrence have an increased risk of progression. The efficacy and safety of enzalutamide plus androgen-deprivation therapy and enzalutamide monotherapy, as compared with androgen-deprivation therapy alone, are unknown.
Methods: In this phase 3 trial, we enrolled patients with prostate cancer who had high-risk biochemical recurrence with a prostate-specific antigen doubling time of 9 months or less. Patients were randomly assigned, in a 1:1:1 ratio, to receive enzalutamide (160 mg) daily plus leuprolide every 12 weeks (combination group), placebo plus leuprolide (leuprolide-alone group), or enzalutamide monotherapy (monotherapy group). The primary end point was metastasis-free survival, as assessed by blinded independent central review, in the combination group as compared with the leuprolide-alone group. A key secondary end point was metastasis-free survival in the monotherapy group as compared with the leuprolide-alone group. Other secondary end points were patient-reported outcomes and safety.
Results: A total of 1068 patients underwent randomization: 355 were assigned to the combination group, 358 to the leuprolide-alone group, and 355 to the monotherapy group. The patients were followed for a median of 60.7 months. At 5 years, metastasis-free survival was 87.3% (95% confidence interval [CI], 83.0 to 90.6) in the combination group, 71.4% (95% CI, 65.7 to 76.3) in the leuprolide-alone group, and 80.0% (95% CI, 75.0 to 84.1) in the monotherapy group. With respect to metastasis-free survival, enzalutamide plus leuprolide was superior to leuprolide alone (hazard ratio for metastasis or death, 0.42; 95% CI, 0.30 to 0.61; P<0.001); enzalutamide monotherapy was also superior to leuprolide alone (hazard ratio for metastasis or death, 0.63; 95% CI, 0.46 to 0.87; P = 0.005). No new safety signals were observed, with no substantial between-group differences in quality-of-life measures.
Conclusions: In patients with prostate cancer with high-risk biochemical recurrence, enzalutamide plus leuprolide was superior to leuprolide alone with respect to metastasis-free survival; enzalutamide monotherapy was also superior to leuprolide alone. The safety profile of enzalutamide was consistent with that shown in previous clinical studies, with no apparent detrimental effect on quality of life. (Funded by Pfizer and Astellas Pharma; EMBARK ClinicalTrials.gov number, NCT02319837.).
Copyright © 2023 Massachusetts Medical Society.
Comment in
-
Enzalutamide in Biochemically Recurrent Prostate Cancer.N Engl J Med. 2024 Jan 4;390(1):90. doi: 10.1056/NEJMc2313228. N Engl J Med. 2024. PMID: 38169497 No abstract available.
-
Enzalutamide in Biochemically Recurrent Prostate Cancer. Reply.N Engl J Med. 2024 Jan 4;390(1):90-91. doi: 10.1056/NEJMc2313228. N Engl J Med. 2024. PMID: 38169498 No abstract available.
Similar articles
-
How the Management of Biochemical Recurrence in Prostate Cancer Will Be Modified by the Concept of Anticipation and Incrementation of Therapy.Cancers (Basel). 2024 Feb 13;16(4):764. doi: 10.3390/cancers16040764. Cancers (Basel). 2024. PMID: 38398155 Free PMC article. Review.
-
Enzalutamide and Quality of Life in Biochemically Recurrent Prostate Cancer.NEJM Evid. 2023 Dec;2(12):EVIDoa2300251. doi: 10.1056/EVIDoa2300251. Epub 2023 Oct 22. NEJM Evid. 2023. PMID: 38320501 Clinical Trial.
-
LBA02-09 EMBARK: A Phase 3 Randomized Study of Enzalutamide or Placebo Plus Leuprolide Acetate and Enzalutamide Monotherapy in High-risk Biochemically Recurrent Prostate Cancer.J Urol. 2023 Jul;210(1):224-226. doi: 10.1097/JU.0000000000003518. Epub 2023 May 2. J Urol. 2023. PMID: 37119051 Clinical Trial.
-
A phase 3 randomised study of enzalutamide plus leuprolide and enzalutamide monotherapy in high-risk non-metastatic hormone-sensitive prostate cancer with rising PSA after local therapy: EMBARK study design.BMJ Open. 2021 Aug 12;11(8):e046588. doi: 10.1136/bmjopen-2020-046588. BMJ Open. 2021. PMID: 34385241 Free PMC article. Clinical Trial.
-
Enzalutamide in Men with Nonmetastatic, Castration-Resistant Prostate Cancer.N Engl J Med. 2018 Jun 28;378(26):2465-2474. doi: 10.1056/NEJMoa1800536. N Engl J Med. 2018. PMID: 29949494 Free PMC article. Clinical Trial.
Cited by
-
A case of severe side effects to androgen receptor inhibitor and consequently switch to radioligand therapy in early castration resistant prostate cancer.Urol Case Rep. 2024 May 11;54:102752. doi: 10.1016/j.eucr.2024.102752. eCollection 2024 May. Urol Case Rep. 2024. PMID: 38779691 Free PMC article.
-
European association of urology biochemical recurrence risk stratification in the context of post-prostatectomy salvage therapy.Transl Androl Urol. 2024 Apr 30;13(4):622-625. doi: 10.21037/tau-23-603. Epub 2024 Apr 9. Transl Androl Urol. 2024. PMID: 38721294 Free PMC article. No abstract available.
-
Salvage Androgen Deprivation Therapy as Potential Treatment for Recurrence after Robot-Assisted Radical Prostatectomy.Cancers (Basel). 2024 Mar 27;16(7):1304. doi: 10.3390/cancers16071304. Cancers (Basel). 2024. PMID: 38610982 Free PMC article.
-
Enzalutamide: Understanding and Managing Drug Interactions to Improve Patient Safety and Drug Efficacy.Drug Saf. 2024 Jul;47(7):617-641. doi: 10.1007/s40264-024-01415-7. Epub 2024 Apr 12. Drug Saf. 2024. PMID: 38607520 Free PMC article. Review.
-
Fatigue in Prostate Cancer: A Roundtable Discussion and Thematic Literature Review.Eur Urol Open Sci. 2024 Apr 4;63:119-125. doi: 10.1016/j.euros.2024.03.003. eCollection 2024 May. Eur Urol Open Sci. 2024. PMID: 38596782 Free PMC article. Review.
Publication types
MeSH terms
Substances
Associated data
Grants and funding
LinkOut - more resources
Full Text Sources
Medical